The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy

Paul M. Young, Jim Thompson, Derek Woodcock, Mo Aydin, Robert Price

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

The performance of a novel dry powder inhaler designed to deliver exceptionally high doses was investigated using pumactant as a model powder. Pumactant (a synthetic lung surfactant consisting of a phospholipid mixture), with a 90th percentile particle size of 2.92 μm is highly cohesive, has a high moisture affinity (6.2% w/w at 45% RH), and is predominately amorphous. The device (pressurized aerosol dry-powder delivery [PADD]) utilizes pressurized gas to aerosolize a powder bed from a reservoir and delivers it through a conventional mouthpiece. The influence of loaded dose on dry powder delivery and can pressure on aerosolization efficiency was investigated. Analysis of the delivered dose studies suggested a linear relationship between loaded dose and delivered dose (R2 = 0.96, for loaded doses of 0–250 mg), with a delivery efficiency of 70%. Analysis of the aerosolization efficiency using a Marple Miller type impactor suggested fine particle fractions (particles with an aerodynamic diameter of <5 μm) of approximately 30% using canister pressures of 8–14 bars. These results indicate that the PADD device may be a useful tool in delivering high-dose medicaments, as a carrier-free formulation, to the deep lung.
Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalJournal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung
Volume17
Issue number2
DOIs
Publication statusPublished - Jun 2004
Externally publishedYes

Keywords

  • device technology
  • high-dose formulations
  • dry powder
  • inhalation pumactant
  • surfactant

Fingerprint

Dive into the research topics of 'The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy'. Together they form a unique fingerprint.

Cite this